Highlights from the 2020 CHDI HD Therapeutics Conference are now here! This year’s Postcard covers HTT-lowering therapeutics, including an
Update on VIBRANT-HD
Update on VIBRANT-HD – Tuesday, August 9, 2022
On Monday, August 8, 2022, Novartis announced their decision to temporarily suspend dosing of the study drug in the Ph2b VIBRANT-HD study of branaplam in adults with Huntington disease (HD). To read more about this decision please visit: https://en.hdbuzz.net/328
While this news is very disappointing, this type of scenario does bring new information in learning more about HD. Our research pipeline contains a variety of potential treatments and is full of hope.
Please remember that HSC Family Services (FS) are available to provide support, education on HD, resources and referrals. Individuals and families can find the contact information for the nearest FS team member here: https://www.huntingtonsociety.ca/family-services-team-list/
Our friends at the Huntington Disease Society of America are hosting a free clinical trials webinar tomorrow, August 11, 2022 at 12pm ET. To register click here: https://hdsa-org.zoom.us/webinar/register/WN_kdgSvfYaRb2aNASNs9xbtw
We would like to highlight the commitment and courage of the HD community members who participate in clinical trials and their families.